Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
3D Medicines (1244 HK)
Watchlist
14
Analysis
Health Care
•
China
3D Medicines Inc. operates as a commercial-stage biopharmaceutical company. The Company focuses on the development of differentiated immuno-oncology drugs. 3D Medicines conducts businesses in China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Alphamab Co Ltd
•
06 Feb 2023 08:55
Alphamab Co Ltd Placement (9966.HK) - Has No Potential to Be a Biopharma; Just Remain as a Biotech
We doubt the competitiveness of Alphamab's products. Its credibility has also been affected. It's more suitable for short-term trade than long-term...
Xinyao (Criss) Wang
Follow
316 Views
Share
bullish
•
Brilliance China Automotive
•
04 Jan 2023 06:29
HSCI Index Rebalance Preview and Stock Connect: A Lot of Change
We forecast 44 adds/19 deletes for the HSCI in March leading to 37 adds/deletes for Southbound Stock Connect. There could be more Connect changes...
Brian Freitas
Follow
813 Views
Share
bearish
•
3D Medicines
•
02 Dec 2022 11:06
Pre-IPO 3D Medicines (3DM HK) - Some Points Worth the Attention; Our Thoughts on Valuation
The overall quality/core competitiveness of 3D Medicines isn't high. Its pipeline is mainly based on license-in model, which is not favored by Mr....
Xinyao (Criss) Wang
Follow
441 Views
Share
bearish
•
3D Medicines
•
24 Aug 2021 09:08
Pre-IPO 3D Medicines - Insights on the Core Product, the Pipeline and the Concerns
This insight mainly analyzed 3D Medicines in terms of its core product envafolimab (the competition pattern and prospects), clinical-stage product...
Xinyao (Criss) Wang
Follow
269 Views
Share
First
Previous
1
2
3
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.33.9
x